Results 121 to 130 of about 304,324 (330)

Identifying Predictive Biomarkers of Response in Patients With Rheumatoid Arthritis Treated With Adalimumab Using Machine Learning Analysis of Whole‐Blood Transcriptomics Data

open access: yesArthritis &Rheumatology, EarlyView.
Objective Tumornecrosis factor inhibitors (TNFi) have significantly improved rheumatoid arthritis (RA) management, yet variability in patient response remains a substantial challenge, with approximately 40% of patients discontinuing TNFi due to nonresponse or adverse effects.
Chuan Fu Yap   +12 more
wiley   +1 more source

LP-027 Overweight and obesity phenotypes based on body mass index and insulin resistance in women with systemic lupus erythematosus

open access: yesLupus Science and Medicine, 2023
Yulia Gorbunova   +4 more
doaj   +1 more source

Antiphospholipid Syndrome: An Antibody‐Mediated Disease With Emerging Therapeutic Opportunities

open access: yesArthritis &Rheumatology, EarlyView.
Antiphospholipid syndrome (APS) is an autoimmune thromboinflammatory disease characterized by vascular thrombosis, pregnancy morbidity, and other manifestations driven by antiphospholipid autoantibodies. In this review, we present a clinical case that illustrates some diagnostic and therapeutic challenges in managing severe, relapsing APS ...
Thalia G. Newman, Jason S. Knight
wiley   +1 more source

LP-026 Obesity, hyperleptinemia and insulin resistance in women with systemic lupus erythematosus and rheumatoid arthritis

open access: yesLupus Science and Medicine, 2023
Yulia Gorbunova   +4 more
doaj   +1 more source

Pharmacodynamic Effects of Litifilimab in Lupus in the LILAC Phase II Study: Rapid and Sustained Reductions in Type I Interferon‐Associated Gene Expression and Cytokines

open access: yesArthritis &Rheumatology, Accepted Article.
Objective The pharmacodynamic effects of litifilimab on type I interferon (IFN) response and correlations with clinical outcomes were investigated in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). Methods Participants from Part A (SLE) or Part B (CLE with/without SLE) of the randomized phase II LILAC trial who received ...
Richard Furie   +8 more
wiley   +1 more source

Loss of TRIM21 drives UVB‐induced systemic inflammation by regulating DNA‐sensing pathways

open access: yesArthritis &Rheumatology, Accepted Article.
Background Patients with systemic lupus erythematosus (SLE) experience photosensitivity, with exposure to ultraviolet light B (UVB) driving lupus flares and triggering symptoms like joint pain, fatigue, and cutaneous lesions. Although the mechanism(s) linking UVB exposure to systemic effects are unclear, type I interferons (IFNs) are known to play a ...
Gantsetseg Tumurkhuu   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy